FDA approves ozanimod for treatment of multiple sclerosis
The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis.
The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The drug is also in advanced clinical development for adults and children with moderate-to-severe ulcerative colitis and Crohn’s disease.
In patient studies supporting ozanimod’s New Drug Application, those who took the once-daily oral medicine experienced significantly less disease progression—including fewer relapses and preservation of the brain from atrophy—than those who received standard care, with very few side effects. The drug, licensed to Bristol Myers Squibb, will be sold under the trademarked name Zeposia.
Related Posts